The submitted protocol outlines a Phase 2b, open-label study designed to generate efficacy and safety data intended to support a future New Drug Application (NDA) for SkinJect® in Gorlin Syndrome.

Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ETUpcoming Data Readout for Cohort 1 of OPGx-BEST1 ...

The medical literature overwhelmingly characterizes the Druze as what researchers call a “genetic isolate,” meaning that ...

Not all broken genes fail in the same way: some simply stop working, while others interfere with what still works.

“In so many ways, [my children] are pioneers, and I could not be prouder of them,” Jillian Arnold tells PEOPLE ...

Not only is the DNA found under Chiara Poggi's nails unidentifiable, but it also "cannot be considered evidence of direct ...

Explore albinism, its causes, impacts, and the importance of empathy in understanding this genetic condition affecting humans and nature.

CCMB scientists have identified an ultra-rare gene mutation linked to red hair in a five-year-old Indian girl, uncovering new ...

A Missouri Army officer killed while a POW in World War II has been identified after decades, bringing long‑awaited answers ...

Her first visit to a hospital was in September 2023, when she was just 16 months old, and her parents noticed she was ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...

The global polycystic kidney disease (PKD) market is expanding rapidly due to rising prevalence, advanced treatments, and increased awareness. The growing cases of chronic kidney diseases (CKD) ...